Inhalable CDK9 Microparticle Composition for Low-Cost R&D Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing inhalable dry particle production methods, such as jet milling and spray drying, are costly and inefficient for producing small quantities of flavopiridol-loaded particles for pulmonary delivery, making them unsuitable for initial research and development efforts.
Innovation Solution
A lab-constructed table-top device is used to produce flavopiridol-loaded inhalable ultra-small particles using a microparticle composition comprising hydrophobic amino acids, lipids, and a cyclin-dependent kinase 9 (CDK9) inhibitor, formed through sonication and drying of a specific reaction mixture.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If spray drying is used to produce inhalable particles, then high throughput production is achieved, but the cost increases significantly and large amounts of drug material are required
Solution Approach 1:
The patent employs a disposable microfluidic device that can be discarded after a single use, eliminating the need for expensive cleanroom facilities and complex sterilization protocols. This single-use approach dramatically reduces manufacturing costs while maintaining GMP compliance, making it suitable for producing inhalable particles at lower costs compared to traditional spray drying methods.
Solution Approach 2:
The patent replaces the mechanical spray drying system with a microfluidic-based droplet generation and drying system. The microfluidic device uses controlled fluid flow and surface tension to generate uniform droplets that are then dried to form particles, eliminating the need for expensive spray drying equipment and reducing overall manufacturing complexity and cost.
2Productivity
If mini spray-drying apparatus is used for R&D, then particle production is achieved, but the equipment cost is extremely high (~$35K)
Solution Approach 1:
The patent uses disposable microfluidic devices that cost fractions of a traditional spray dryer, enabling R&D laboratories to produce inhalable particles without investing in expensive equipment. These single-use devices are pre-sterilized and can be discarded after one experiment, eliminating the need for costly maintenance and validation.
Solution Approach 2:
The patent extracts the essential particle formation function from the complex spray drying system and implements it in a simplified microfluidic platform. By taking out only the necessary droplet generation and drying capabilities and removing the expensive ancillary equipment, the system achieves particle production at a fraction of the cost.
3Adaptability or versatility
If systemic delivery (i.v. or oral) is used for anti-inflammatory medicines, then broad distribution is achieved, but high dosage and severe side effects occur
Solution Approach 1:
The patent formulates the anti-inflammatory drug as inhalable particles that deliver the medication directly to the lungs, creating a local high concentration at the target site while maintaining low systemic levels. This local quality approach allows effective treatment of lung inflammation, cancer, and COVID-19 with reduced side effects compared to systemic delivery.
Solution Approach 2:
The patent uses inhalable particles as an intermediary carrier that transports the drug directly to the lung tissue. These particles act as a mediator between the administered drug and the target cells, enabling localized delivery and reducing the need for high systemic doses that cause severe side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device efficiently produces particles that meet physio-chemical requirements for pulmonary delivery, demonstrating anti-inflammatory activity in vitro and showing promise for treating lung inflammation, lung cancer, and COVID-19.
Implementation Method 1
The feed mixture is applied to a microfluidic piezo array and sonicated to form a spray of fine droplets
Implementation Method 2
The feed mixture is applied to a microfluidic piezo array and sonicated to form a spray of fine droplets
Implementation Method 3
a microparticle composition comprising a hydrophobic amino acid or a hydrophobic peptide, or combinations thereof; a lipid; and a cyclin-dependent kinase 9 (CDK9) inhibitor
Data Source
AI summary
The present disclosure describes a formulation for the delivery of CDK9 inhibitors.